NEWS COMMENTARY

World's first Alzheimer's drug in 20 years gets conditionally approved in China

Published:
November 05, 2019
Coverage:
Digital Transformation More...
Activities:
Markets More...
by Nardev Ramanathan
Very important

The development of the drug, Oligomannate, was inspired by the observation that elderly people who consumed seaweed had an extremely low incidence of Alzheimer’s disease. Shanghai Green Valley Pharmaceuticals plans to launch the product in China by the end of the year, with global Phase 3 trials planned in the U.S., EU, and other parts of Asia to support regulatory submissions worldwide. This is an interesting development, as the drug is claimed to not just treat but potentially reverse the condition as well. Clients should wait for more data after product launch and from the global Phase 3 trials and note that the Chinese government's approval was not unconditional, indicating more data is still needed on long-term safety and efficacy.

For the original news article, click here .


Further Reading

Heterocyclic lipids conjugated to mRNA vaccines increase anti-tumor efficacy

News Commentary | October 01, 2019

A team at the Koch Institute for Integrative Cancer Research and the Massachusetts Institute of Technology identified lipid nanoparticles that not only aid in the delivery of scalable RNA vaccines but also act as adjuvants, boosting a vaccine's effectiveness. This is a solution to an ongoing issue ... To read more, click here.

U.S. FDA approves first Chinese cancer drug for use in American patients

News Commentary | November 18, 2019

The accelerated approval is ahead of even China's own national drug regulator. The drug is a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy and is the first in a raft of cancer drugs the FDA is readying for regulatory approval. In a vote of ... Not part of subscription

Advanced BioNutrition and GreenLight Biosciences collaborate on RNAi solutions

News Commentary | August 23, 2019

The collaboration will apply ABN's (Lux Take: Engage) preservation and slow‑release technology to move GreenLight's (Lux Take: Monitor) RNAi technology to productization. Last year, GreenLight emerged as a front‑runner for the development of RNAi solutions, and it now refers to its scalable RNA ... Not part of subscription